This area addresses important aspects to improve therapeutic outcome for selected disease entities and to identify novel drug targets. While the research concepts rely on our longstanding PGx expertise at the IKP, they will be substantially complemented by innovative multiOmics and integrated bioinformatic and biostatistical analyses. To this end it is important to appreciate that drug efficacy and resistance mechanisms in cancer depend not only on the patients constitution, but also on features of the tumor, for example its heterogeneity and TME. Accordingly, our novel discovery strategies require the consideration of both, the tumor and patient genome. In particular, the application of comprehensive -omics approaches covering genetic, epigenetic and metabolic patterns, should enable the better understanding of the underlying mechanisms of drug response. Notably, all our approaches are strengthened by the thorough integration of bioinformaticians, as members of the research groups, and their computational tools, thereby dwelling on our past achievements.
